Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone).

UNLABELLED Copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) (copper-ATSM) is a hypoxia-avid tracer for the selective identification of hypoxic tissue. Using canine models of hypoxic myocardium, we report our findings on *Cu-ATSM PET (*Cu is defined as either (60)Cu, (61)Cu, or (64)Cu) for the delineation of ischemic and hypoxic myocardium. METHODS In protocol I, myocardial hypoxia was induced by global hypoxia (n = 3). In protocol II, myocardial ischemia was generated by occlusion of the left anterior descending coronary artery (n = 9). In protocol III, coronary artery stenosis was induced by a stenosis in the left anterior descending coronary artery (n = 4). PET dynamic data were acquired immediately after tracer injection. Tracer retention kinetics were analyzed using either monoexponential analysis (1/k(mono)) or a simple 2-compartment model (1/k(4)). RESULTS In protocol I, tracer retention in hypoxic myocardium was 2-fold greater than in normal myocardium, despite a 7-fold increase in blood flow (normal, 0.70 +/- 0.42 mL.min(-1).g(-1); hypoxic, 4.94 +/- 3.00 mL.min(-1).g(-1) [P < 0.005]). In protocol II, approximately 3 h after occlusion, retention of *Cu-ATSM within 20 min was greater in ischemic regions (myocardial blood flow, 0.28 +/- 0.26 mL.min(-1).g(-1)) than in normal tissue (myocardial blood flow, 0.52 +/- 0.19 mL.min(-1).g(-1)) (1/k(mono), 40.72 +/- 39.0 min vs. 26.69 +/- 22.29 min [P < 0.05]; 1/k(4), 6.85 +/- 4.90 min vs. 3.51 +/- 1.97 min [P < 0.05]). In selected dogs, tracer retention decreased at 24 h, suggesting the development of necrosis with no subsequent retention of *Cu-ATSM. In protocol III, dobutamine infusion after stenosis placement resulted in increased tracer retention consistent with hypoxia in the damaged regions. CONCLUSION *Cu-ATSM PET has shown quantitative selective uptake in hypoxic myocardium within 20 min of tracer administration in 3 canine models of hypoxia.

[1]  Jason S. Lewis,et al.  Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships , 2002, JBIC Journal of Biological Inorganic Chemistry.

[2]  C. Ling,et al.  On measuring hypoxia in individual tumors with radiolabeled agents. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Harumi Itoh,et al.  Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia , 2001, Annals of nuclear medicine.

[4]  M. Welch,et al.  A research resource in radionuclide research , 2001 .

[5]  Y. Fujibayashi,et al.  Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  S Mutic,et al.  A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[7]  J. Lacy,et al.  Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  P. Cutler,et al.  High purity production and potential applications of copper-60 and copper-61. , 1999, Nuclear medicine and biology.

[9]  G. Johnson,et al.  HL-91-Technetium-99m: A new marker of viability in ischemic myocardium , 1999, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[10]  Zhonglin Liu,et al.  99mTc-HL91: "hot spot" detection of ischemic myocardium in vivo by gamma camera imaging. , 1998, Circulation.

[11]  Y Yonekura,et al.  Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  C. Ng,et al.  Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia. , 1995, Circulation.

[13]  W. Rumsey,et al.  Effect of graded hypoxia on retention of technetium-99m-nitroheterocycle in perfused rat heart. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  A. Nunn,et al.  Nitroimidazoles and imaging hypoxia , 1995, European Journal of Nuclear Medicine.

[15]  M. Parliament,et al.  Imaging tumor hypoxia and tumor perfusion. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  M J Welch,et al.  Quantification of Regional Myocardial Perfusion With Generator‐Produced 62Cu‐PTSM and Positron Emission Tomography , 1993, Circulation.

[17]  M. Graham,et al.  Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  L. Golberg,et al.  Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. , 1992, British Journal of Cancer.

[19]  M. Raichle,et al.  Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  C. Dence,et al.  In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. , 1990, Journal of the American College of Cardiology.

[21]  Y. Yonekura,et al.  A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  P. Herrero,et al.  Quantitation of myocardial blood flow with H2 15O and positron emission tomography: assessment and error analysis of a mathematical approach. , 1989, Journal of computer assisted tomography.

[23]  S. Cain,et al.  Metabolic and circulatory responses of normoxic skeletal muscle to whole-body hypoxia. , 1989, Journal of applied physiology.

[24]  C. Dence,et al.  Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  M. Cerqueira,et al.  Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  B. Sobel,et al.  Characterization of the functional significance of subcritical coronary stenoses with H(2)15O and positron-emission tomography. , 1985, Circulation.

[27]  M. Ter-pogossian,et al.  Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. , 1982, The American journal of medicine.

[28]  R. Kloner,et al.  Early pathologic detection of acute myocardial infarction. , 1981, Archives of pathology & laboratory medicine.

[29]  M. Fishbein,et al.  Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. , 1981, American heart journal.

[30]  Ronald H. Huesman,et al.  Imaging Properties of a Positron Tomograph with 280 Bgo Crystals , 1981, IEEE Transactions on Nuclear Science.

[31]  G. Robinson,et al.  THE ZINC‐62/COPPER‐62 GENERATOR: A CONVENIENT SOURCE OF COPPER‐62 FOR RADIOPHARMACEUTICALS , 1980, The International journal of applied radiation and isotopes.

[32]  Y. Fujibayashi,et al.  Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  Y. Yonekura,et al.  Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. , 1999, Nuclear medicine and biology.

[34]  S. Barrington,et al.  Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  M J Welch,et al.  Efficient production of high specific activity 64Cu using a biomedical cyclotron. , 1997, Nuclear medicine and biology.

[36]  M. Green A potential copper radiopharmaceutical for imaging the heart and brain: copper-labeled pyruvaldehyde bis(N4-methylthiosemicarbazone). , 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.